IL-16 antagonists
First Claim
1. An isolated IL-16 antagonist peptide consisting of CLLS.
1 Assignment
0 Petitions
Accused Products
Abstract
In accordance with the present invention, novel IL-16 antagonists, preferably peptides derived from CD4, have been isolated and synthesized. These peptides possess IL-16 antagonistic properties including the ability to selectively bind to IL-16 and inhibit IL-16-mediated biological activity. The peptides comprise specific portions of the native human CD4 receptor and variations thereof and therefore are non-immunogenic when administered to humans. The present invention also provides compositions containing at least one IL-16 antagonist peptide which can inhibit, suppress or cause the cessation of at least one IL-16-mediated biological activity in mammals, including humans.
The present invention provides a method and composition for treating inflammation associated with disease states such as asthma, rheumatoid arthritis, inflammatory bowel disease (IBD) and systemic lupus (SLE) in mammals such as, for example, humans.
-
Citations
28 Claims
- 1. An isolated IL-16 antagonist peptide consisting of CLLS.
-
2. An isolated IL-16 antagonist peptide of any one of WQCLLS, WQALLS, VVQVVA or VKQVVA.
-
3. An isolated IL-16 antagonist peptide consisting of GMWQCLLS (SEQ ID NO:
- 13).
-
4. An isolated peptide consisting of GMWQCLLSDSGQVLLE (SEQ ID NO:
- 12)
-
5. An isolated peptide consisting of any one of TGLWQCLLSEGD (SEQ ID NO:
- 14) or VSEEQKVVQVVA (SEQ ID NO;
15).
- 14) or VSEEQKVVQVVA (SEQ ID NO;
- 6. An IL-16 antagonist peptide comprising Xaa1-LL-Xaa2 wherein Xaa1 and Xaa2 is any amino acid (SEQ ID NO:
-
8. An IL-16 antagonist peptide comprising CLLS (SEQ ID NO:
- 2).
- 9. An IL-16 antagonist peptide comprising Xaa1-Xaa2-Xaa3-L-L-Xaa4 wherein Xaa1-Xaa4 is any amino acid (SEQ ID NO:
-
12. An IL-16 antagonist peptide comprising WQCLLS (SEQ ID NO:
- 4) or WQALLS (SEQ ID NO;
5).
- 4) or WQALLS (SEQ ID NO;
-
13. An IL-16 antagonist peptide comprising Xaa1-Val-Xaa2-Val-Xaa3-Xaa4 wherein Xaa1-Xaa4 is an amino acid (SEQ ID NO:
- 8).
-
15. An IL-16 antagonist peptide comprising VVQVVA (SEQ ID NO:
- 9) or VVQKVA (SEQ ID NO;
11).
- 9) or VVQKVA (SEQ ID NO;
-
16. An IL-16 antagonist peptide comprising GMWQCLLS (SEQ ID NO:
- 13).
-
17. An IL-16 antagonist peptide comprising GMWQCLLSDSGQVLLE (SEQ ID NO:
- 12).
-
26. An IL-16 antagonist.
-
27. A pharmaceutical composition comprising an IL-16 antagonist and a pharmaceutically acceptable carrier.
-
28. A method of treating an IL-16 mediated disorder comprising blocking the interaction of IL-16 with an IL-16 receptor by the administration of an IL-16 antagonist.
Specification